GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
122 articles in GLP-1 & Metabolic · page 8 of 11
GLP-1s and Cholesterol: Secondary Metabolic Effects
Weight is not the only marker that moves on a GLP-1. What the lipid data from the semaglutide trials shows, and how much is weight loss.
Read →Survodutide and the GLP-1/Glucagon Approach
A GLP-1/glucagon dual agonist with phase 2 MASH and obesity data. What is verified, what is not, and how it differs from GLP-1s.
Read →GLP-1 Shortages: What Drove Them and What's Next
Demand outran supply for years. What caused it, when the FDA called it resolved, and what that then changed for compounding.
Read →GLP-1s and the Gut Microbiome
A 2025 review found 38 studies but only 9 in humans, with inconsistent diversity results. The thread is real; conclusions aren't.
Read →Generic GLP-1s: When Will Prices Fall?
Generic liraglutide arrived in 2024-2025; semaglutide and tirzepatide are protected far longer. The real price timeline.
Read →Protein Intake on a GLP-1: Why It Matters More
DEXA data shows ~40% of GLP-1 weight loss can be lean mass. Why protein and resistance training matter more when appetite drops.
Read →GLP-1s and Cognitive Health: Early Signals
Researchers studied GLP-1s in the brain, and the largest Alzheimer's trials came back negative. What the early signals were, and what remains.
Read →Tirzepatide for Heart Failure: The SUMMIT Trial
Tirzepatide cut heart-failure events in obesity-related HFpEF in the SUMMIT trial. What that result does and doesn't show.
Read →GLP-1s and 'Food Noise': The Science of Reduced Cravings
The most striking patient-reported GLP-1 effect may point to the brain's reward circuitry, not just the gut. What that implies.
Read →Will GLP-1s Work for You? Predicting Response
Response varies widely. What controlled trials say about who loses the most — and the real limits of predicting it upfront.
Read →GLP-1s and Exercise: A Better-Together Story
GLP-1 weight loss includes lean mass. Why resistance training changes what kind of weight you lose, and what the trials measured.
Read →GLP-1s in Type 2 Diabetes vs Obesity: Different Goals
Same drug class, different endpoints, doses, and expectations depending on why it was prescribed. How diabetes and obesity use diverge.
Read →